You are here

Study of PKI-179 Administered Orally to Subjects With Solid Tumors

Last updated on March 11, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Malignant Solid Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Male or female subjects age 18 years or older.

2. Part 1/MTD Estimation Phase: Pathologic diagnosis of any solid tumor. Part 2/MTD
Confirmation Phase: Pathologic diagnosis of one of the following tumor types: breast,
non-small cell lung, ovarian, endometrial, or colorectal cancer or glioblastoma.

3. Availability of either formalin-fixed paraffin-embedded (FFPE) tumor tissue block or
unstained slides for exploratory biomarker analysis.

4. Incurable cancer, with disease progression following at least 1 conventional,
standard, or investigational therapy with no further standard treatment available in
the opinion of the investigator.

5. At least 1 evaluable lesion as defined by Response Evaluation Criteria in Solid Tumors
(RECIST) criteria.

6. Eastern Cooperative Oncology Group (ECOG) 0 to 2.

7. Acceptable laboratory values, including fasting serum glucose.

8. All male and female subjects who are biologically capable of having children, must
agree to use a medically acceptable method of birth control for the duration of the
study (e.g., condom with a spermicide) and for 12 weeks after the last dose of
investigational product. All female subjects who are biologically capable of having
children must have a negative serum pregnancy test result before first dose of
investigational product. Any pregnancy that occurs in the female partner of a male
subject in the trial must be reported if it occurs at any time during the active
treatment phase of the study or for 12 weeks after the last dose of investigational
product.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Major surgery, chemotherapy, radiotherapy, investigational therapy, or other cancer
therapy within 2 weeks prior to first dose of investigational product.

2. Lack of recovery from any prior surgery, chemotherapy, radiotherapy, or other cancer
therapy.

3. Clinically unstable primary or metastatic central nervous system (CNS) tumors.
Subjects with progression of CNS tumors are eligible as long as they have been
clinically stable for at least 4 weeks before first dose of PKI-179 (no significant
change in anticonvulsant doses, mental status, or clinical symptoms related to the CNS
tumors).

4. Subjects with known diabetes.

5. QTc interval > 470 ms.

6. Pregnant or breastfeeding women.

7. Evidence of significant medical illness or abnormal laboratory finding that in the
opinion of the investigator would substantially increase the risk associated with the
subject's participation in the study or impact the assessment of safety and/or
efficacy. Examples include, but are not limited to: uncontrolled seizures, serious
ongoing active infection requiring treatment, significant uncontrolled cardiac
disease, such as congestive heart failure, myocardial infarction within past 6 months,
angina requiring treatment, or other clinically significant or uncontrolled
conditions.

NCT00997360
Pfizer
Withdrawn
Study of PKI-179 Administered Orally to Subjects With Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now